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Implementation of locally adapted guidelines on
type 2 diabetes
Rykel van Bruggena, Kees J Gortera, Roland P Stolkb, Rob P
Verhoevenc and Guy E H M Ruttena
van Bruggen R, Gorter KJ, Stolk RP, Verhoeven RP and Rutten GEHM. Implementation of locally
adapted guidelines on type 2 diabetes. Family Practice 2008; 25: 430–437.
Objective. To assess the effects of a facilitator enhanced multifaceted intervention to imple-
ment a locally adapted guideline on the shared care for people with type 2 diabetes.
Methods. During 1 year a cluster-randomized trial was performed in 30 general practices. In the
intervention group, nurse facilitators enhanced guideline implementation by analysing barriers
to change, introducing structured care, training practice staff and giving performance feedback.
Targets for HbA1c%, systolic blood pressure as well as indications for angiotensin converting en-
zyme/angiotensin receptor blocking agent prescription differed from the national guidelines. In
the control group, GPs were asked to continue the care for people with diabetes as usually. Gen-
eralized estimating equations were used to control for the clustered design of the study.
Results. In the intervention group, more people were seen on a 3-monthly basis (88% versus
69%, P < 0.001) and more blood pressure and bodyweight measurements were performed every
3 months (blood pressure 83% versus 66%, P < 0.001 and bodyweight 78.9% versus 48.5%, P <
0.001). Apart from a marginal difference in mean cholesterol, differences in HbA1c%, blood pres-
sure, body mass index and treatment satisfaction were not significant.
Conclusion. Multifaceted implementation of locally adapted shared care guidelines did im-
prove the process of diabetes care but hardly changed intermediate outcomes. In the short term,
local adaptation of shared care guidelines does not improve the cardiovascular risks of people
with type 2 diabetes.
Keywords. Chronic disease management, diabetes, randomized controlled trial.
Introduction
Clinical practice guidelines are considered effective
tools to improve the quality of diabetes care.1 Their
implementation, however, has not been straightfor-
ward. It has become evident that passive dissemina-
tion of guidelines is largely ineffective and only rarely
induces a behavioural change.2 Successful implemen-
tation strategies, therefore, are active and targeted at
different levels of care (professional, team, patient
and organization).3 Such strategies must be adequately
resourced and include systems for training and evalua-
tion.4 Recently, a Cochrane review concluded that
multifaceted interventions can improve the treatment
of people with diabetes, as can organizational inter-
ventions that improve the recall and tracking of these
people.5 In general, multifaceted interventions target-
ing different barriers to change are more likely to be
effective than single interventions.6 Furthermore, phy-
sician support and feedback by trained facilitators
proved to be helpful in improving glycaemic control7
and appeared to increase the rates of foot and eye ex-
amination in general practice.8 Finally, it has been
suggested that end-user involvement in the develop-
ment and adaptation of national guidelines can result
in an increased uptake.9 A systematic review sug-
gested that the use of a local consensus process was
more likely to lead to the effective implementation of
clinical guidelines.10 A more recent study, on the other
hand, did not find any additional effect from the local
adaptation process itself.11 Hence, it is questionable
whether local adaptation of national guidelines is an
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essential prerequisite to ensuring improvements in the
quality of care.
In an effort to improve the quality of diabetes care
and reduce disease-related costs, much attention is
paid to different models of diabetes care like shared
care, integrated care and disease management. Espe-
cially, disease management is expected to succeed
were other approaches have failed. Systematic reviews
support this view,12,13 but recognize important limita-
tions of the original studies, including lack of consen-
sus about what constitutes disease management. In
The Netherlands, much attention is paid to the con-
cept of shared care. Physicians, nurses and paramedics
are called upon to implement multidisciplinary shared
care guidelines to minimize the risks for patients with
chronic diseases. However, randomized controlled tri-
als supporting this view are rare.
We report the results of a multifaceted facilitator
enhanced intervention aimed at the implementation
of a local guideline on the shared care for people with
type 2 diabetes.
Research design and methods
The study was carried out in and around Apeldoorn,
a city with 150 000 inhabitants in The Netherlands. It
was a cluster-randomized trial comparing usual care
with care according to locally adapted shared care
guidelines, taking clustering at a practice level into ac-
count14 The Medical Ethical Committee of the Uni-
versity Medical Centre Utrecht approved the protocol
and all participants gave informed consent.
Study participants
We asked all primary care practices in the greater
Apeldoorn region (n = 70) to participate. In the 30
participating practices, the lists of people diagnosed
with type 2 diabetes were updated prior to the start of
the study. For this purpose, a computer search was
performed using the following terms: Anatomical
Therapeutic Chemical code A10 (insulin and oral hy-
poglycaemic agents), International Classification of
Diseases in Primary Care code T90 (diabetes) and dia-
betes (text word). Then, the files of all tracked people
were checked for the type of diabetes. Only people
with type 2 diabetes (n = 3357) were considered eligi-
ble for the present study. Exclusion criteria were the
inability to complete a questionnaire, severe mental
illness, unwillingness to attend the practice regularly
or a limited life expectancy. As it was our aim to in-
vestigate the effect of the implementation of local
shared care guidelines in primary care, people being
treated at the outpatient clinic of the local hospital
were excluded as well.
Randomization
Participating general practices were randomized into
an intervention and control group. Prior to randomiza-
tion, practices were divided into groups according to
the following criteria: practice type (single handed,
duo or group practice) and presence of a specialized
nurse. An independent researcher then carried out
a restricted randomization procedure using a random
number table to ensure equal numbers of practices in
each group.
Multifaceted interventions
Intervention practices were encouraged to treat peo-
ple with type 2 diabetes in accordance with the lo-
cally adapted shared care guidelines. A working
committee of four GPs, two internists from the local
hospital, three diabetes nurse specialists and two die-
ticians based these guidelines on the national guide-
lines for the treatment of type 2 diabetes of the
Dutch College of General Practitioners.15 Due to
new insights, distinct differences arose between both
guidelines (Box 1). Control group practices were
asked to continue the care for people with diabetes
in line with the national guidelines.15
BOX 1 Differences between the guidelines of the Dutch College of General Practitioners and the local shared care guidelines
Dutch College of General Practitioners guidelines Locally adapted shared care guidelines
HbA1c >8.5% considered poor glycaemic control HbA1c >8% considered poor glycaemic control
After diagnosis, all people are treated with lifestyle intervention. If
necessary, oral hypoglycaemic agents after 3 months
After diagnosis, people with fasting blood glucose >15 mmol/l are
immediately treated with lifestyle intervention and oral
hypoglycaemic agents
Recommended blood pressure <150/85 Recommended blood pressure <140/85
Patients with life expectancy >5 years and a 10 years cardiovascular risk
>25% are treated with statins
Patients with life expectancy >5 years and a 10 years CV risk
>20% are treated with statins
People with microalbuminurea <50 years are treated with angiotensin
converting enzyme inhibitors
People with microalbuminurea <60 years are treated with angiotensin
converting enzyme inhibitors or ATII receptor antagonists
No rules for referral back to primary care Explicit rules for referral back to primary care
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In the intervention group practices, two nurse spe-
cialists interviewed practice staff, analysed barriers to
change, discussed means to overcome these barriers
and handed out abstracts of the guidelines on plasti-
cized sheets. These nurses, trained as facilitators, vis-
ited all intervention practices two times per month for
approximately 3 hours. During these visits, they trained
the GPs, practice assistants and nurses in the use of the
guidelines, encouraged the introduction of structured
diabetes care, emphasized the need for 3-monthly con-
trol and gave assistance in managing people with type
2 diabetes. Performance feedback was given 6 months
after the start of the intervention. We used the method
described by Kiefe and others to formulate achievable
benchmarks of care.16,17 These benchmarks represent
in essence the average performance for the top 10% of
the physicians (practices) being assessed.
Measurements
Diabetes care providers examined all participants at
the start of the study and approximately 1 year later
at study completion. Demographics, duration of diabe-
tes, smoking habits, co-morbidity and presence of
macrovascular or microvascular complications were
recorded. Standard operating procedures were used to
record weight, height, waist and hip circumference
and blood pressure. Fasting blood samples and urine
samples were obtained and analyzed at the labora-
tory of the local hospital. HbA1c% was determined
by the Variant II Turbo Haemoglobin Testing System
(Bio-Rad Laboratories, Hercules, USA). Plasma
glucose, total cholesterol, high density lipoprotein
cholesterol, triglycerides, albumin/creatinin ratio
and microalbumen were determined with the Archi-
tect ci8200SR (Abbott Park, Illinois, USA). The
health-related quality of life was estimated with the
EuroQol-5D (range –0.59 to 1, where 1 indicates per-
fect health) and the validated Dutch version of the
disease-specific diabetes health profile (range 0–100,
where 100 represents no dysfunction).18,19 To de-
scribe the overall health state of the participants, we
used the visual analogue scale of the EuroQol-5D
(range 0–100). The satisfaction of the participants
with their treatment was measured with the Dutch
version of the diabetes treatment satisfaction ques-
tionnaire (range 0–36).20
All 18 pharmacists in the Apeldoorn region took
part in our study. To obtain a complete medication
file, we used their files and those of three GPs keeping
their own pharmacy. We selected the complete medi-
cation histories of all participants using hypoglycaemic
medication (ATC code A10) or being diagnosed by
their GP with type 2 diabetes.
Statistical analysis
Three-monthly measurements of fasting blood glucose
(FBG), blood pressure and bodyweight and the
prescription of ATII antagonists or ACE inhibitors in
case of microalbuminuria were considered to be indi-
cators of the process of care. As primary outcome
measure, we used the percentage of people with poor
glycaemic control at baseline that achieved an HbA1c
of <8%. Mean HbA1c%, total cholesterol, diastolic
and systolic blood pressure, quality of life and treat-
ment satisfaction were used as secondary outcome
measurements. Participants’ level of formal education
was split into two categories. People who visited pri-
mary school only or primary and secondary school at
a non-advanced level were considered to have a low
level of formal education. All others were regarded as
highly educated. Student’s t-test and chi-square test
were used where appropriate. All analyses were by in-
tention to treat. Based on literature and clinical rea-
soning, we identified the following potential
confounders: age, gender, level of education, micro-
and macrovascular complications, insulin use and
quality of life. Generalized estimating equations
(GEE) models were used to construct multivariable
regression models, while controlling for potential con-
founders and the clustered design of the study. Statisti-
cal significance was set at P < 0.05 two sided. Except
for the GEEs, all analyses were carried out using the
statistical package SPSS version 12.0 for Windows.
We used SAS software version 8 (SAS Institute, Cary,
NC) for the GEEs models.
Sample size calculations were based on the assump-
tion that at baseline 30% of the participants would
have an HbA1c >8.0%. A sample size of 288 would
provide 80% power to detect a 30% reduction in the
number of these participants. In order to adjust for
clustering at practice level, we then multiplied this
sample size by a design effect of 2.62 (based on an in-
tra-class correlation coefficient of 0.034), thus requir-
ing a total sample size of 817 people with type 2
diabetes in each study group.
Part of the participants had missing values. Ignoring
cases with a missing value (complete case analysis)
may lead to biased results and loss of power.21 There-
fore, we imputed missing values using the regression
method available in SPSS. The imputation was based
on the correlation between each variable with missing
values and all other variables as estimated from the
subjects with complete data.
Results
Participants
In total, 11 single handed, 16 duo and three group
practices agreed to participate. Reasons for non-par-
ticipation were a lack of time, a dislike of research
projects, a lack of confidence in the outcome of the
study and the conviction that the practice performed
well and did not need improvement of diabetes care.
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In 45% of the participating solo practices, specialized
nurses were concerned with diabetes care; in the duo
and group practices, this percentage was 56 and 67, re-
spectively. Overall, 2983 people with type 2 diabetes
were eligible. Of these people, 2042 gave informed
consent. In all, 1640 participants were treated within
primary care (Fig. 1).
Baseline characteristics
Except for education and the presence of macrovas-
cular complications, patients’ characteristics were
highly comparable across study groups. In the inter-
vention group, more participants had a low level of
formal education. Controls were more often suffering
from macrovascular complications. About 50% of the
participating people with type 2 diabetes were men.
Mean age of the participants was approximately 67
years (Table 1).
Process and outcome of care
After 1 year, process measures differed significantly
between the intervention and the control group, ex-
cept for the prescription rate of angiotensin-blocking
agents and ACE inhibitors. These differences re-
mained significant after we controlled for age, gen-
der, level of education, micro- and macrovascular
complications, insulin use, quality of life and the clus-
tered design of the study (Table 2).
FIGURE 1 Flow sheet of the sampling process
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In the intervention group, more initially poorly con-
trolled participants reached adequate glycaemic con-
trol at the end of the study (70% versus 58%, P <
0.05). This difference became non-significant after
controlling for baseline value, potential confounders
and clustering at practice level. After 1 year, we were
unable to demonstrate significant differences in
HbA1c, blood pressure, body mass index (BMI) and
treatment satisfaction between both study groups.
There was, however, a small but statistically significant
difference in mean cholesterol after the implementa-
tion of the locally adapted guidelines. This difference
remained statistically significant after we controlled
for baseline value, potential confounders and the clus-
tered study design. At study completion, the percen-
tages of initially poorly controlled people that reached
adequate blood pressure or lipid control were equal
across study groups (Tables 3 and 4).
Barriers
The barriers most commonly identified were lack of
time, lack of knowledge on the content of the guide-
line, lack of financial incentives, lack of motivation
and reluctance to prescribe multiple drug regimens.
Training practice staff on the job, organizing educa-
tional meetings and making comparisons with peers
levelled these barriers. Furthermore, the nurses gave
advice on insulin type and dosage in people with poor
glycaemic control.
Referrals
Nearly 3% of all participants were referred to the out-
patient’s clinic to receive secondary diabetes care (in-
tervention group 2.8%, control group 2.9%; P = 0.9).
From the outpatient clinic of the local hospital, many
people were referred back to primary care (24.7% ver-
sus 23.3%, P = 0.7).
Discussion
The facilitator enhanced implementation of a locally
adapted guideline on type 2 diabetes led to a significant
increase in the number of people with type 2 diabetes
that were seen on a 3-monthly basis. During the inter-
vention, bodyweights and blood pressures of the par-
ticipants were also registered more often. At the end
of the study, there were no significant differences in
the percentages of people that reached adequate con-
trol of their diabetes, blood pressure or BMI. Mean
cholesterol improved 0.1 mmol/l, while other cardio-
vascular risk factors remained unchanged.
Some limitations of this study need to be discussed.
Firstly, as people under secondary care were excluded
from this study, we are not informed about the effects
of the implementation of the guidelines on the quality
of secondary diabetes care. However, as randomization
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HbA1c (%) 7.0 (1.1) 7.1 (1.2)
Systolic blood
pressure (mmHg)
145.8 (18.4) 145.7 (20.0)
Diastolic blood
pressure (mmHg)
82.5 (9.1) 82.9 (9.3)
Cholesterol (mmol/l) 5.3 (1.0) 5.2 (1.0)
BMI (kg/cm2) 29.7 (5.6) 29.0 (5.3)
EuroQol-5D 0.81 (0.20) 0.79 (0.22)
EuroQol-VAS 76.3 (16.0) 74.3 (16.2)
DHP 85.4 (9.4) 84.4 (10.2)
DTSQ 31.8 (5.3) 31.5 (5.2)
VAS, visual analogue scale; DHP, diabetes health profile; DTSQ, di-
abetes treatment satisfaction questionnaire.
TABLE 2 Process measures in intervention and control group
Intervention (SD) Control (SD) P P* P**
FBG every 3 months (%) 87.8 68.6 <0.001 <0.001 <0.001
Blood pressure every 3 months (%) 82.5 65.4 <0.001 <0.001 <0.01
Bodyweight every 3 months (%) 78.9 48.5 <0.001 <0.001 <0.001
Angiotensin converting enzyme inhibitor or angiotensin receptor
blocking agent prescribed according to guideline (%)
67.4 65.1 0.7 0.4 0.6
FBG, fasting blood glucose.
P: unadjusted. P*: controlled for age, gender, level of education, micro- and macrovascular complications, insulin use and quality of life. P**: con-
trolled for age, gender, level of education, micro- and macrovascular complications, insulin use, quality of life and clustering at practice level.
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took place within primary care, secondary care physi-
cians were treating participants from both study groups
and therefore had knowledge on the content of the
guidelines. It would have been very difficult for
these specialists to treat half of the participants in
accordance with the local guidelines and the other
half as usually. It is more likely that they would
have treated all people with type 2 diabetes more or
less in accordance with the local guidelines. This
would most certainly have diluted the effect of our
intervention. Secondly, baseline measurements were
performed in the intervention as well as the control
group. These measurements necessitated the recall
and registration of all people with type 2 diabetes.
As registration and recall are fundamental to the
quality of diabetes care, their introduction may have
enhanced the quality of care in the control practices.
Possibly, this strategy reduced the contrast between
the intervention and the control group and thus the
potential to detect a positive effect of the interven-
tion. Thirdly, when selecting people we may have
missed those receiving dietary treatment only. How-
ever, as we scrutinized the medical records not only
for ATC code A10 but also for ICPC code T90 and
the text word diabetes, we are confident that most
patients on a diet were labelled as having diabetes.
Furthermore, the percentage of patients on a diet in
our study was 20%. This percentage is in line with
the percentages found in several other Dutch stud-
ies.22–24 Fourthly, the sample size calculation of our
study was based on the assumption that about 30%
of the participants would have an HbA1c of >8%.22
At study completion, participants’ glycaemic control
proved to be much better than expected. Therefore,
our study might have been hampered by a lack of
power. Finally, the use of a single imputation proce-
dure may have resulted in an underestimation of the
standard errors or too small P-values.25
The results of this study are in line with recent pub-
lications. Most large-scale quality improvement initia-
tives show only modest improvements in some
process measures, but fail to demonstrate better inter-
mediate or end-stage outcomes.26 This may be illus-
trated by a recent study on diabetes shared care,
a large-scale controlled study on the effects of the
Health Disparities Collaborative and a recent study
on the impact of a quality improvement intervention
on the quality of diabetes care at primary care clin-
ics.27–29 Notwithstanding, significant improvements in
diabetes care delivery none or only minor improve-
ments in intermediate outcomes were found. A Dutch
study produced more optimistic results. After the
TABLE 3 Outcome measures in intervention and control group, all patients
Intervention (SD), n = 822 Control (SD), n = 818 P P* P**
HbA1c <8.0% (%) 90.1 86.8 <0.05 0.07 0.1
Blood pressure <140/85 mmHg (%) 23.1 24.2 0.6 0.6 0.7
Cholesterol <5 mmol/l (%) 46.4 46.0 0.9 0.3 0.3
BMI <27 (%) 33.0 36.9 0.1 0.9 0.9
HbA1c (%) 6.9 (0.9) 7.0 (1.0) <0.01 <0.05 0.1
Systolic blood pressure (mmHg) 146.3 (18.7) 146.8 (19.1) 0.6 0.4 0.9
Diastolic blood pressure (mmHg) 81.9 (9.3) 82.4 (9.7) 0.3 0.2 0.5
Cholesterol (mmol/l) 5.1 (1.0) 5.2 (1.0) 0.2 <0.01 <0.05
BMI (kg/cm2) 29.6 (5.1) 29.0 (5.1) <0.05 0.8 0.8
DTSQ 32.4 (4.3) 32.1 (4.4) 0.1 0.3 0.3
DTSQ, diabetes treatment satisfaction questionnaire.
P: unadjusted. P*: controlled for baseline value, age, gender, level of education, micro- and macrovascular complications, insulin use and quality of
life. P**: controlled for baseline value, age, gender, level of education, micro- and macrovascular complications, insulin use, quality of life and clus-
tering at practice level.
TABLE 4 Percentages of initially poorly controlled people with type 2 diabetes that reached adequate control
Intervention (SD) Control (SD) P P* P**
HbA1c <8.0% (%) 70.4 (n = 125) 57.6 (n = 139) <0.05 0.1 0.2
Blood pressure <140/85 mmHg (%) 15.5 (n = 633) 16.4 (n = 605) 0.7 0.9 0.9
Cholesterol <5 mmol/l (%) 29.7 (n = 472) 26.3 (n = 441) 0.3 0.2 0.2
BMI <27 (%) 9.3 (n = 540) 8.8 (n = 501) 0.8 0.6 0.6
P: unadjusted. P*: controlled for baseline value, age, gender, level of education, micro- and macrovascular complications, insulin use and quality of
life. P**: controlled for baseline value, age, gender, level of education, micro- and macrovascular complications, insulin use, quality of life and clus-
tering at practice level.
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introduction of structured shared care with task dele-
gation to nurses, significant improvements in the pro-
cess parameters and achieved target values at the
individual patient level could be demonstrated.24
However, as this was a non-randomized study, the re-
sults can only be indicative. Multiple studies have
stressed the importance of local tailoring of an inter-
national or national guideline.9,10,30–32 Local adapta-
tion has been described as a key element in guideline
implementation. However, randomized trials support-
ing this view are sparse. One randomized trial found
significant changes in knowledge, attitude and re-
ported practice as a result of disseminating guidelines,
but it did not find any additional effect from the local
adaptation process itself.11 Our findings are in line
with these results. As it was our aim to evaluate the ef-
fect of a locally adapted guideline under the best pos-
sible circumstances, we thought it unwise to enhance
usual care by employing nurse facilitators in control
group practices. Therefore, these facilitators gave at-
tention to intervention group practices only. Given
the fact that we were unable to demonstrate significant
differences in both primary and secondary outcomes
of our study, it is unlikely that local adaptation under
less optimal circumstances will improve the intermedi-
ate outcomes of diabetes care.
One may wonder why our multifaceted intervention
did not induce any improvement in the cardiovascular
risk factors. A Danish study into structured personal
diabetes care is a rare example of a randomized con-
trolled trial showing a significant improvement in
blood pressure at study completion.33 This study lasted
for 6 years, suggesting that a better outcome may fol-
low an improved process of care over time. Clearly,
the outcome of care is highly influenced by the ability
of physicians to adjust the patients’ regimen in time.
Grant et al. 34 demonstrated that although the testing
rates for HbA1c, blood pressure and total cholesterol
in a national sample of US academic medical centres
were very high, only 10.0% of this cohort met recom-
mended goals for all three risk factors. Apparently,
high rates of risk factor testing did not necessarily
translate to effective metabolic control. A recent
Canadian study confirmed these results: less than one-
half of the people with high HbA1c levels had inten-
sification of their medications, regardless of the
specialty of their physician.35 Failure of health care
providers to initiate or intensify therapy when indi-
cated has been called clinical inertia.36 Clinical inertia
seems to be widespread and is probably a major bar-
rier to better diabetes care. Therefore, the results of
our study may be explained, at least partially, by the
failure to intensify therapy appropriately. Implementa-
tion of diabetes guidelines is likely to be more effec-
tive if energy is spent to overcome clinical inertia
instead of local adaptation of nationally agreed target
values, prescription rules and referral indications.
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